A Phase 2, randomized, double-blind, placebo-controlled study to investigate the safety and efficacy in reducing nasal allergen challenge provoked symptoms of treatment with DM-101PX in adults with birch pollen allergic rhinitis or rhinoconjunctivitis.
If you are interested in participating in this clinical trial, please fill out the contact form below to speak to one of our Research Coordinators to find out if this study is right for you.
A Phase 2, randomized, double-blind, placebo-controlled study to investigate the safety and efficacy in reducing nasal allergen challenge provoked symptoms of treatment with DM-101PX in adults with birch pollen allergic rhinitis or rhinoconjunctivitis.
The overall purpose of the study is to evaluate the safety and tolerability of treatment with DM101PX and its efficacy in reducing symptoms provoked by Nasal Allergen Challenge (NAC) with birch pollen extract in individuals with moderate to severe birch pollen-induced allergic rhinitis or rhinoconjunctivitis.
To be eligible for this study, you must be:
18 - 65 years of age
Allergic to birch pollen
This is not a complete list of eligibility criteria. The study doctor will review the full entry criteria for this study with you.
Please complete the form below if you are interested in learning more about this study and would like to schedule a phone call with one of our coordinators to discuss further.